1 Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health, 2018;6: e555–67.
2 Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med, 2006;354: 34–43.
3 Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst, 2003;95: 105–12.
4 Ledermann J A, Raja F A, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2013;24 Suppl 6: vi24–32.
5 Chan JK, Tian C, Teoh D, Monk BJ, Herzog T, Kapp DS, et al.Survival after recurrence in early-stage high-risk epithelial ovarian cancer: A Gynecological Oncology Group Study. Gynecologic Oncology, 2010;116:307–11
6 Polcher M, Friedrichs N, Rudlowski C, Fimmer R, Keyver- Paik MD, Kübler K, et al.Changes in Ki–67 labeling indices during neoadjuvant chemotherapy for advanced ovarian cancer are associated with survival. Int J Gynecol Cancer, 2010;20: 555–60.
7 Kim H, Kim K, No J H, Jeon YT, Jeon HW, Kim YB. Prognostic value of biomarkers related to drug resistance in patients with advanced epithelial ovarian cancer. Anticancer Res, 2012;32: 589–94.
8 Chen M, Yao S, Cao Q, Xia M, Liu J, He M. The prognostic value of Ki67 in ovarian high-grade serous carcinoma: an 11-year cohort study of Chinese patients. Oncotarget, 2017;8: 107877–85.
9 Garcia-Velasco A, Mendiola C, Sanchez-Munoz A, Ballestín C, Colomer R, Cortés-Funes H. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol, 2008;10: 367–71.
10 Ditto A, Leone Roberti Maggiore U, Bogani G, Martinelli F, Chiappa V, Evangelista MT,et al. Predictive factors of recurrence in patients with early-stage epithelial ovarian cancer. Int J Gynaecol Obstet. 2019;14:28–33.
11 Kajiyama H, Mizuno M, Shibata K, Yamamoto E, Kawai M, Nagasaka T, et al. Recurrence-predicting prognostic factors for patients with early-stage epithelial ovarian cancer undergoing fertility-sparing surgery: a multi-institutional study. Eur J Obstet Gynecol Reprod Biol, 2014;175: 97–102.
12 Karagol H, Saip P, Eralp Y, Topuz S, Berkman S, Ilhan R, et al. Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer. Tumori, 2009;95:207–11.
13 Chang C, Chiang A J, Chen W A, et al. A joint model based on longitudinal CA125 in ovarian cancer to predict recurrence. Biomark Med,2016; 10: 53–61.
14 Rizzuto I, Stavraka C, Chatterjee J, Borley J, Hopkins TG, Gabra H, et al. Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer. Int J Gynecol Cancer, 2015;25: 416–22.
15 Lenhard S M, Bufe A, Kumper C, Stieber P, Mayr D, Hertlein L, et al. Relapse and survival in early-stage ovarian cancer. Arch Gynecol Obstet, 2009;280: 71–7.
16 Yang Z J, Zhao B B, Li L. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer. J Ovarian Res, 2016;9: 57.
17 Sieh W, Kobel M, Longacre T A, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol, 2013;14: 853–62.
18 Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J, et al. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer, 2013;23: 25–33.